Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability

American Journal of Medicine

Volumn 128, Issue 9, 2015, Pages S1-S15

  Culpepper, Larry ^a   Muskin, Philip R ^b   Stahl, Stephen M ^c,d,e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Efficacy; Individualized Treatment; Major depression; Measurement based care; Multimodal antidepressants; Residual Symptoms

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; ESCITALOPRAM; FLUOXETINE; LEVO METHYLFOLATE; LIOTHYRONINE; LITHIUM; MECAMYLAMINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OMEGA 3 FATTY ACID; OPIATE; PINDOLOL; PSYCHOTROPIC AGENT; QUETIAPINE; S ADENYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE; VORTIOXETINE; NEUROLEPTIC AGENT;

ADD ON THERAPY; ARTICLE; COGNITIVE BEHAVIORAL THERAPY; COMBINATION DRUG THERAPY; COMORBIDITY; DEPRESSION ASSESSMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; FUNCTIONAL DISEASE; HUMAN; INSOMNIA SEVERITY INDEX; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROBIOLOGY; PAIN SEVERITY; PATIENT COMPLIANCE; PATIENT HEALTH QUESTIONNAIRE 9; PATIENT REFERRAL; PERSONALIZED MEDICINE; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIST; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUESTIONNAIRE; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; SHEEHAN DISABILITY SCALE; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WORK AND SOCIAL ADJUSTMENT SCALE; DEPRESSIVE DISORDER, MAJOR;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MOLECULAR TARGETED THERAPY; MONOAMINE OXIDASE INHIBITORS; PSYCHOTROPIC DRUGS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84947298814     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.07.001     Document Type: Article

References (107)

1. Kessler, R.C., Chiu, W.T., Demier, O., Walters, E.E., Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 62 (2005), 617–627.
2. Kessler, R.C., Barber, C., Birnbaum, H.G., et al. Depression in the workplace: effects on short-term disability. Health Affairs 18 (1999), 163–171.
3. Adler, D.A., McLaughlin, T.J., Rogers, W.H., Chang, H., Lapitsky, L., Lerner, D., Job performance deficits due to depression. Am J Psychiatry 163 (2006), 1569–1576.
4. Greenberg, P.E., Kessler, R.C., Birnbaum, H.G., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 64 (2003), 1465–1475.
5. Stahl, S.M., Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed., 2013, Cambridge University Press, New York, NY.
6. McIntyre, R.S., Fallu, A., Konarski, J.Z., Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther 28 (2006), 1882–1891.
7. Zimmerman, M., McGlinchey, J.B., Posternak, M.A., Friedman, M., Attiulah, N., Boerescu, D., How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 163 (2006), 148–150.
8. Fava, G.A., Ruini, C., Belaise, C., The concept of recovery in major depression. Psychol Med 37 (2007), 307–317.
9. Miller, I.W., Keitner, G.I., Schatzberg, A.F., et al. Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59 (1998), 608–619.
10. Judd, L.L., Paulus, M.J., Schettier, P.J., et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry 157 (2000), 1501–1504.
11. Papakostas, G.I., Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 70:suppl 6 (2009), 16–25.
12. Thase, M.E., Update on partial response in depression. J Clin Psychiatry 70:suppl 6 (2009), 4–9.
13. Paykel, E.S., Residual symptoms and relapse in depression. Medicographia 31 (2009), 157–163.
14. Nierenberg, A.A., Husain, M.M., Trivedi, M.H., et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40 (2010), 41–50.
15. Paykel, E.S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., Barocka, A., Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25 (1995), 1171–1180.
16. Mrazek, D.A., Hornberger, J.C., Altar, C.S., Degtiar, I., A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv 65 (2014), 977–987.
17. Trivedi, M.H., Corey-Lisle, P.K., Guo, Z., Lennox, R.D., Pikalov, A., Kim, E., Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 24 (2009), 133–138.
18. McKnight, P.E., Kashdan, T.B., The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 29 (2009), 243–259.
19. Romera, I., Pérez, V., Quail, D., Berggren, L., Lenox-Smith, A., Gilaberte, I., Individual residual symptoms and functional impairment in patients with depression. Psychiatry Res 220 (2014), 258–262.
20. Romera, I., Pérez, V., Menchón, J.M., Polavieja, P., Gilaberte, I., Optimal cutoff point of the Hamilton Rating Scale for Depression according to normal levels of social and occupational functioning. Psychiatry Res 186 (2011), 133–137.
21. Zimmerman, M., McGlinchey, J.B., Posternak, M.A., Friedman, M., Boerescu, D., Attiulah, N., Differences between minimally depressed patients who do and do not consider themselves to be in remission. J Clin Psychiatry 66 (2005), 1134–1138.
22. Zimmerman, M., Posternak, M.A., Chelminski, I., Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high?. J Nerv Ment Dis 193 (2005), 170–175.
23. Trivedi, M.H., Evaluating and monitoring treatment response in depression using measurement-based assessment and rating scales. J Clin Psychiatry, 74, 2013, e14.
24. Sheehan, K.H., Sheehan, D.V., Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23 (2008), 70–83.
25. Spitzer, R.L., Kroenke, K., Williams, J.B.W., the Patient Health Questionnaire Primary Care Study Group. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA 282 (1999), 1737–1744.
26. Kroenke, K., Spitzer, R.L., The PHQ-9: a new depression diagnostic and severity measure. Psychiatric Ann 32 (2002), 1–7.
27. Angstman, K.B., Rasmussen, N.H., MacLaughlin, K.L., Staab, J.P., Inter-relationship of the functional status question of the PHQ-9 and depression remission after six months of collaborative care management. J Psychiatr Res 47 (2013), 418–422.
28. Daly, E.J., Trivedi, M.H., Wisniewski, S.R., et al. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry 22 (2010), 43–55.
29. Mundt, J.C., Marks, I.M., Shear, M.K., Greist, J.H., The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 180 (2002), 461–464.
30. Endicott, J., Nee, J., Harrison, W., Blumenthal, R., Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29 (1993), 321–326.
31. Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., Nierenberg, A.A., Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 28 (2011), 137–144.
32. Conradi, H.J., Ormel, J., de Jonge, P., Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 41 (2011), 1165–1174.
33. Romera, I., Pérez, V., Ciudad, A., et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry, 13, 2013, 51.
34. Fried, E.I., Nesse, R.M., The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One, 9, 2014, e90311.
35. Muskin, P.R., Major depressive disorder and other medical illness: a two-way street. Ann Clin Psychiatry 22:suppl 3 (2010), S15–S20.
36. Stahl, S.M., Psychotherapy as an epigenetic ‘drug’: psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. J Clin Pharmacol Ther 37 (2012), 249–253.
37. Stahl, S.M., The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illness. CNS Spectrums 18 (2013), 65–68.
38. Shelton, R.C., Tomarken, A.J., Can recovery from depression be achieved?. Psychiatric Serv 52 (2001), 1469–1478.
39. Nierenberg, A.A., Keefe, B.R., Leslie, V.C., et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60 (1999), 221–225.
40. Nierenberg, A.A., DeCecco, L.M., Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62:suppl 16 (2001), 5–9.
41. Stahl, S.M., Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectrums 18 (2013), 113–117.
42. Stahl, S.M., Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor. CNS Spectrums 19 (2014), 105–109.
43. Montgomery, S.A., Nielson, R.Z., Poulsen, L.H., Häggström, L., A randomized, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Human Psychopharmacol 29 (2014), 470–482.
44. Pehrson, A.L., Sanchez, C., Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums 19 (2014), 121–123.
45. Schwartz, T.L., Stahl, S.M., Optimizing antidepressant management of depression: current status and future perspectives. Mod Trends Pharmacopsychiatry 27 (2010), 254–267.
46. Stahl, S.M., Combining antidepressant therapies from initiation of treatment: a paradigm shift for major depression. J Clin Psychiatry 70 (2009), 1493–1494.
47. Stahl, S.M., Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectrums 15 (2010), 79–94.
48. Blier, P., Ward, H.E., Tremblay, P., Laberge, L., Hébert, C., Bergeron, R., Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167 (2010), 281–288.
49. Rush, A.J., Trivedi, M.H., Stewart, J.W., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168 (2011), 689–701.
50. Wiles, N., Thomas, L., Abel, A., et al. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomized controlled trial. Heath Technol Assess 18 (2014), 1–167.
51. Hollon, S.D., DeRubeis, R.J., Fawcett, J., et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 71 (2014), 1157–1164.
52. Culpepper L (ed). Academic highlights: recognizing and treating the physical symptoms of depression in primary care. Prim Care Companion J Clin Psychiatry. 2004;6:168-188.
53. Zajecka, J.M., Treating depression to remission. J Clin Psychiatry 64:suppl 15 (2003), 7–12.
54. Mann, J.J., The medical management of depression. N Engl J Med 353 (2005), 1819–1834.
55. Tylee, A., Identifying and managing depression in primary care in the United Kingdom. J Clin Psychiatry 67:suppl 6 (2006), 41–45.
56. American Psychiatric Association (APA), Practice guidelines for the treatment of patients with major depressive disorder. 3rd ed. Am J Psychiatry 167:suppl (2010), 1–152.
57. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in Star*D: implications for clinical practice. Am J Psychiatry 163 (2006), 28–40.
58. Robinson, R.L., Stephenson, J.J., Denney, E.B., et al. The importance of unresolved fatigue in depression: costs and comorbidities. Psychosomatics 56 (2015), 274–285.
59. Saveanu, R., Etkin, A., Duchemin, A.M., et al. The International Study to Predict Optimized Treatment in Depression (ISPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatry Res 61 (2015), 1–12.
60. Hirschfeld, R.M.A., Keller, M.B., Panico, S., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277 (1997), 333–340.
61. Corey-Lisle, P.K., Nash, R., Stang, P., Swindle, R., Response, partial response and nonresponse in primary care treatment of depression. Arch Intern Med 164 (2004), 1197–1204.
62. Stewart, J.W., Delivannides, D.A., McGrath, P.J., How treatable is refractory depression?. J Affect Disord 167 (2014), 148–152.
63. Berlim, M.T., Fleck, M.P., Turecki, G., Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med 40 (2008), 149–159.
64. DeBattista, C., Augmentation and combination strategies for depression. J Psychopharmacol 20:3 suppl (2006), 11–18.
65. Youdim, M.B., Edmondson, D., Tipton, K.F., The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7 (2006), 295–309.
66. Patkar, A., Pae, C.U., Massand, P.S., Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectrums 11 (2006), 363–365.
67. Vandenberg, C.M., MAOIs and transdermal delivery. J Clin Psychiatry, 73, 2012, e28.
68. Culpepper, L., Kovalick, L.J., A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry 10 (2008), 25–30.
69. Grady, M.M., Stahl, S.M., Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectrums 17 (2012), 2–10.
70. Culpepper, L., Reducing the burden of difficult-to-treat major depressive disorder: revisiting monoamine oxidase inhibitor therapy. Prim Care Companion CNS Disorders, 15(5), 2013 pii: PCC.13r01515.
71. El-Khalili, N., Joyce, M., Atkinson, S., et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13 (2010), 917–932.
72. Berman, R.M., Marcus, R.N., Swanink, R., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68 (2007), 843–853.
73. Marcus, R.N., McQuade, R.D., Carson, W.H., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28 (2008), 156–165.
74. Nelson, J.C., Papakostas, G.I., Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166 (2009), 980–991.
75. Papakostas, G.I., Fava, M., Thase, M.E., Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63 (2008), 699–704.
76. Connolly, K.R., Thase, M.E., If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination, and switching strategies. Drugs 71 (2011), 43–64.
77. Carpenter, L.L., Yasmin, S., Price, L.H., A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51 (2002), 183–188.
78. 12, and s-adenosylmethionine. Psychiatr Clin North Am 36 (2013), 1–13.
79. Carpenter, D.J., St. John's wort and s-adenosyl methionine as “natural” alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?. Altern Med Rev 16 (2011), 17–39.
80. Freeman, M.P., Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 70:suppl 5 (2009), 7–11.
81. Lin, P.Y., Huang, S.Y., Su, K.P., A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 68 (2010), 140–147.
82. Peet, M., Horrobin, D.F., A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59 (2002), 913–919.
83. Gertsik, L., Poland, R.E., Bresee, C., Rapaport, M.H., Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 32 (2012), 61–64.
84. Sublette, M.E., Ellis, S.P., Geant, A.L., Mann, J.J., Meta-analysis: effects of eicosapentaenoic acid in clinical trials in depression. J Clin Psychiatry 72 (2011), 1577–1584.
85. Papakostas, G.I., Shelton, R.C., Zajecka, J.M., et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 75 (2014), 855–863.
86. Fava, G.A., Thase, M.E., DeBattista, C., Doghramji, K., Arora, S., Hughes, R.J., Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 19 (2007), 153–159.
87. Trivedi, M.H., Fava, M., Wisniewski, S.R., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354 (2006), 1243–1252.
88. Maes, M., Libbrecht, I., van Hunsel, F., Campens, D., Meltzer, H.Y., Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19 (1999), 177–182.
89. Perry, E.B., Berman, R.M., Sanacora, G., Anand, A., Lynch-Colonese, K., Charney, D.S., Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 65 (2004), 238–243.
90. Ballesteros, J., Callado, L.F., Effectiveness of pindolol plus serotonin reuptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79 (2004), 137–147.
91. Thase, M.E., Rush, A.J., When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58:suppl 13 (1997), 23–29.
92. Thase, M.E., Rush, A.J., Howland, R.H., et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 59 (2002), 233–239.
93. Freeman, M.P., Freeman, S.A., Lithium: clinical considerations in internal medicine. Am J Med 119 (2006), 478–481.
94. Bauer, M., Dopfmer, S., Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19 (1999), 427–434.
95. Hage, M.P., Azar, S.T., The link between thyroid function and depression. J Thyroid Res 2012 (2012), 1–8.
96. Aronson, R., Offman, H.J., Joffe, R.T., Naylor, C.D., Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 53 (1996), 842–848.
97. Papakostas, G.I., Cooper-Kazaz, R., Appelhof, B.C., et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 245 (2009), 19–25.
98. Joffe, R.T., Singer, W., Levitt, A.J., MacDonald, C., A placebo-controlled comparison of lithium and triiodothyroninie augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50 (1993), 387–393.
99. Nierenberg, A.A., Fava, M., Trivedi, M.H., et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163 (2006), 1519–1530.
100. Kennedy, S.H., Giacobbe, P., Treatment-resistant depression—advances in somatic therapies. Ann Clin Psychiatry 19 (2007), 279–287.
101. Lam, R.W., Chan, P., Wilkins-Ho, M., Yatham, L.N., Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Can J Psychiatry 53 (2008), 621–631.
102. Olfson, M., Marcus, S.C., Tedeschi, M., Wan, G.J., Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 163 (2006), 101–108.
103. Simon, G.E., Von Korff, M., Wagner, E.H., Barlow, W.L., Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 15 (1993), 399–408.
104. Lin, E.H.B., Von Korff, M., Katon, W., et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care 33 (1995), 67–74.
105. Aikens, J.E., Nease, D.E. Jr., Klinkman, M.S., Explaining patients’ beliefs about the necessity and harmfulness of antidepressants. Ann Fam Med 6 (2008), 23–29.
106. Bull, S.A., Hu, X.H., Hunkeler, E.M., et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 288 (2002), 1403–1409.
107. Katon, K., Von Korff, M., Lin, E., et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA 273 (1995), 1026–1031.